AstraZeneca reports positive data from two phase III Symbicort studies

AstraZeneca has reported new clinical data showing the effectiveness of the drug Symbicort in the treatment of chronic obstructive pulmonary disease (COPD) and asthma.

The company has announced the results of RISE and CHASE 3, two international multicentre studies involving adult and paediatric patients, which showed that the inhalation aerosol was well tolerated and achieved its primary endpoints in both studies.

In the RISE study, AstraZeneca's drug was shown to be effective in reducing exacerbations in adult patients with moderate to very severe COPD, while the CHASE 3 trial showed its benefits in the treatment of children with asthma.

Results from both of these trials will be used to support future regulatory submissions for the therapy.

Greg Keenan, vice-president and head medical officer for AstraZeneca's US medical affairs business, said: "Positive results from the RISE and CHASE 3 studies reinforce Symbicort as an important treatment option for respiratory patients across a broad range of age groups."

This comes after the firm reported new phase III clinical trial data last month demonstrating the benefits of its new antibiotic product Zavicefta.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.